Stocks · News reference
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10
Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
Analysts upgraded Copart, Orchestra BioMed, Illumina, Martin Marietta Materials and Waters, raising their price targets.
Crude Oil Surges 6%; Macy’s Shares Fall After Q2 Results
U.S. stocks fell Thursday as the Dow dropped 300+ points; Macy’s slid on weak guidance, while oil rose and producer prices accelerated.
Orchestra BioMed shares are trading higher after BTIG upgraded the stock from Neutral to Buy rating and announced a $10 price target.